S. Matheny

发表

Involvement of Neuropilin-1 in the autocrine mechanism of Vascular Endothelial Growth Factor-165 in breast cancer progression

S. Matheny, 2003 .

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

P. Kantoff, S. Larson, M. Morris, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

M. Erlander, J. Neal, H. Wakelee, 2016 .

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Daniel J Brat, Erwin G. Van Meir, D. Brat, 2005, Neuro-oncology.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

H. Wakelee, L. Sequist, S. Ou, 2014 .

Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.

F. Saad, H. Scher, J. Bono, 2013 .

VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms

U. Thorgeirsson, G. Merlino, V. Factor, 2005, Laboratory Investigation.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

BAI1 regulates spatial learning and synaptic plasticity in the hippocampus.

Erwin G. Van Meir, J. Olson, Y. Smith, 2015, The Journal of clinical investigation.

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001

M. Embry, R. Stafford, R. Henningsen, 2023, Oncotarget.

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

H. Wakelee, L. Sequist, S. Ou, 2016 .

Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.

F. Saad, J. Bono, E. Small, 2014 .

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

J. Burke, J. Leonard, A. Krishnan, 2020 .

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001

M. Embry, R. Stafford, Xiaofan Li, 2018, Oncotarget.

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).

F. Braiteh, R. Schilder, D. Uyar, 2021 .

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC).

K. Fizazi, Margaret K Yu, N. Tran, 2013 .

A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial.

E. Small, S. Shreeve, Margaret K Yu, 2014 .

Vascular endothelial growth factor‐D is a survival factor for human breast carcinoma cells

U. Thorgeirsson, E. Okajima, Amy Shah, 2006, International journal of cancer.

Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs

Tina Koestler, H. Wakelee, L. Sequist, 2015 .

Association of Radiographic Progression-Free Survival (RPFS) Adapted from Prostate Cancer Working Group 2 (PCWG2) Consensus Criteria (APCWG2) with Overall Survival (OS) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC): Results from COU-AA-302

S. Larson, M. Morris, H. Scher, 2012 .

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.